Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Core Insights - Athira Pharma has secured a deal to test a promising breast cancer drug, indicating a strategic shift in its focus [1] - The company has also obtained $90 million in upfront funding from investors, which will support its research and development efforts [1] Company Developments - The deal for the breast cancer drug represents a significant pivot for Athira Pharma, suggesting a potential expansion of its therapeutic portfolio [1] - The $90 million funding is a crucial financial boost that will enable the company to advance its clinical trials and further its drug development initiatives [1]